Routledge P A, O'Mahony M S, Woodhouse K W
Department of Pharmacology, Therapeutics and Toxicology, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN, Wales, UK.
Br J Clin Pharmacol. 2004 Feb;57(2):121-6. doi: 10.1046/j.1365-2125.2003.01875.x.
Many studies from around the world show a correlation between increasing age and adverse drug reaction (ADR) rate, at least for some medical conditions. More than 80% of ADRs causing admission or occurring in hospital are type A (dose-related) in nature, and thus predictable from the known pharmacology of the drug and therefore potentially avoidable. Frail elderly patients appear to be particularly at risk of ADRs and this group is also likely to be receiving several medicines. The toxicity of some drug combinations may sometimes be synergistic and be greater than the sum of the risks of toxicity of either agent used alone. In order to recognize and to prevent ADRs (including drug interactions), good communication is crucial, and prescribers should develop an effective therapeutic partnership with the patient and with fellow health professionals. Undergraduate and postgraduate education in evidence-based therapeutics is also vitally important. The use of computer-based decision support systems (CDSS) and electronic prescribing should be encouraged, and when problems do occur, health professionals need to be aware of their professional responsibility to report suspected adverse drug events (ADEs) and ADRs. "Rational" or "obligatory" polypharmacy is becoming a legitimate practice as increasing numbers of individuals live longer and the range of available therapeutic options for many medical conditions increases. The clear risk of ADRs in this situation should be considered in the context that dose-related failure of existing therapy to manage the condition adequately may be one of the most important reasons for admission of the elderly to hospital. Thus, age itself should not be used as a reason for withholding adequate doses of effective therapies.
全球许多研究表明,年龄增长与药物不良反应(ADR)发生率之间存在关联,至少在某些医疗状况下如此。导致入院或在医院发生的ADR中,超过80%本质上属于A型(剂量相关型),因此可根据药物已知的药理学知识预测,进而有可能避免。体弱的老年患者似乎尤其容易发生ADR,而且这一群体可能同时服用多种药物。某些药物组合的毒性有时可能具有协同作用,且大于单独使用任何一种药物的毒性风险之和。为了识别和预防ADR(包括药物相互作用),良好的沟通至关重要,开处方者应与患者以及其他医疗专业人员建立有效的治疗合作关系。循证治疗学的本科和研究生教育也至关重要。应鼓励使用基于计算机的决策支持系统(CDSS)和电子处方,当出现问题时,医疗专业人员需要意识到他们有专业责任报告疑似药物不良事件(ADE)和ADR。随着越来越多的人寿命延长,以及针对许多医疗状况的可用治疗选择范围扩大,“合理”或“必要”的多药联合使用正成为一种合理的做法。在这种情况下,应考虑到ADR的明显风险,因为现有治疗在剂量相关方面无法充分控制病情可能是老年人入院的最重要原因之一。因此,年龄本身不应被用作拒绝给予足够剂量有效治疗的理由。